D81.31 Severe combined immunodeficiency due to adenosine deaminase deficiency

Name of the Condition

• Severe combined immunodeficiency due to adenosine deaminase deficiency

Summary

Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency is a rare inherited disorder that severely impairs the immune system, leading to a lack of functional T cells, B cells, and natural killer cells. This condition results from genetic mutations that reduce or eliminate the activity of the ADA enzyme, causing a buildup of toxic metabolites that damage immune cells and disrupt their development. Without treatment, individuals with this disorder are highly susceptible to recurrent, severe infections and typically do not survive beyond early childhood.

Causes

ADA deficiency is caused by genetic mutations in the ADA gene, which provides instructions for producing the adenosine deaminase enzyme. These mutations disrupt the enzyme's function, leading to the accumulation of toxic substances that destroy lymphocytes. The condition is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disorder. Carriers (those with one mutated copy) typically do not show symptoms.

Risk Factors

• Genetic predisposition, often with a family history of immunodeficiency disorders.
• Consanguinity (parents who are closely related) increasing the risk of autosomal recessive forms.

Symptoms

• Recurrent, severe, or persistent infections (e.g., bacterial, viral, fungal).
• Failure to thrive or delayed growth in infants and children.
• Chronic diarrhea or gastrointestinal issues.
• Skin rashes or infections.
• Persistent thrush (oral candidiasis).
• Absence of tonsils or lymph nodes.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and genetic testing. Blood tests may show low lymphocyte counts, abnormal immune function, and elevated toxic metabolites. Enzyme activity assays can confirm reduced ADA levels, and genetic testing identifies mutations in the ADA gene. Newborn screening for SCID may also detect the condition early.

Treatment Options

Treatment focuses on restoring immune function and may include enzyme replacement therapy (PEG-ADA), hematopoietic stem cell transplantation (HSCT), or gene therapy. Supportive care, such as antibiotics for infections and immunoglobulin replacement, is often necessary. Early intervention is critical to improve outcomes.

Prognosis and Follow-Up

With early diagnosis and appropriate treatment, prognosis can improve significantly. HSCT or gene therapy may provide long-term immune reconstitution, but outcomes depend on the timing of treatment and the presence of complications. Lifelong monitoring for infections and immune function is essential.

Complications

• Recurrent, life-threatening infections (e.g., pneumonia, sepsis).
• Failure to thrive or developmental delays.
• Increased risk of certain cancers due to impaired immune surveillance.
• Adverse reactions to treatments (e.g., graft-versus-host disease in HSCT).

Lifestyle & Prevention

• Avoid exposure to infections (e.g., crowds, sick contacts).
• Practice good hygiene (handwashing, avoiding raw foods).
• Follow vaccination guidelines tailored to immune status.
• Genetic counseling for families with a history of the disorder.

When to Seek Professional Help

Seek immediate medical attention for:

• Fever or signs of infection (e.g., cough, diarrhea, rash).
• Unusual or severe symptoms in infants (e.g., poor feeding, lethargy).
• Family history of immunodeficiency disorders.

Tips for Medical Coders

Document the specific diagnosis of severe combined immunodeficiency due to ADA deficiency clearly. Include clinical details (e.g., enzyme levels, genetic test results) to support coding. Ensure the code D81.31 is used when the condition is specifically attributed to adenosine deaminase deficiency, distinguishing it from other SCID subtypes.